AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
The National Medical Products Administration (NMPA) in China has granted approval for Dupixent® (dupilumab) as an add-on maintenance treatment for adults suffering from uncontrolled chronic obstructive pulmonary disease (COPD) characterized by elevated blood eosinophils. This significant advancement in COPD management specifically applies to patients already using a combination of inhaled corticosteroids (ICS), long-acting beta2-agonists (LABA), and long-acting muscarinic antagonists (LAMA), or those on a LABA and LAMA regimen when ICS is not suitable.
COPD is a debilitating respiratory condition affecting millions globally, and the burden is particularly acute in China, where one in four COPD patients resides. According to Professor Kang Jian, Chair of the COPD Branch at the Chinese Association of Chest Physicians, the ramifications of COPD extend beyond the individual, impacting families and caregivers. “Debilitating breathlessness and irreversible lung damage make it difficult for patients to perform simple daily tasks,” Professor Kang noted. The approval of Dupixent in China is vital as it introduces a targeted therapeutic option for patients inadequately managed even after undergoing triple therapy.
George D. Yancopoulos, M.D., Ph.D., Board co-Chair and President at Regeneron, emphasized the importance of this approval: “With millions of people in industrialized areas worldwide facing an increased risk for developing COPD, it is crucial to deliver innovative new options for this complex and notoriously difficult-to-treat disease.” Dupixent has demonstrated groundbreaking results in clinical trials, significantly reducing exacerbations while improving lung function and enhancing the overall quality of life for patients.
Dupixent is not new to the global stage; it has received approval for COPD treatment in over 30 countries, including all 27 nations in the European Union. The drug has established itself as a vital option in managing severe asthma, eczema, and other chronic conditions, making its extension to COPD a logical and promising step forward.
Despite the prevalence of COPD in China, public awareness remains alarmingly low. The Chinese government’s Healthy China 2030 initiative aims to tackle chronic respiratory diseases, including COPD, by focusing on improving the quality of life for affected individuals. Increased education and awareness are critical to ensure that patients recognize symptoms early and seek appropriate treatment.
The approval of Dupixent for COPD by the NMPA marks a significant milestone in the fight against this challenging respiratory disease in China. It represents a new hope for millions of patients and their families who have struggled with inadequate treatment options. As healthcare providers gain access to this innovative therapy, it is essential to continue promoting awareness about COPD and its management.
